Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression
December 5, 2023
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumor
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Companies to leverage Skyhawk's proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets.
Skyhawk Therapeutics Completes New Investment Round
A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.
